Stirling talking to potential partners for HDA device

According to Stirling Products, the company is in discussions with several major pharmaceutical companies about partnerships on products using its patented high density aerosol (HDA) device. The company says that its ultrasound-based HDA technology produces a concentration level three times higher than that of other ultrasonic devices. One version of the device has 510(k) approval, and Stirling says that it is developing more advanced versions. Read the company’s press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan